Loading…
Lobbying Income
$1.7M
Filings
75
Unique Clients
2
Active Period
2009–2025
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $20,000
Matched citations: H.R 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $20,000
Matched citations: S.726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and Wellness education programs focused on chronic disease - -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $110,000
Matched citations: H.R 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and Wellness education programs focused on chronic disease - -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $110,000
Matched citations: H.R 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and Wellness education programs focused on chronic disease - -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $110,000
Matched citations: S.726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Client: PHRMA (ON BEHALF OF WE WORK FOR HEALTH)
-The impact of medical innovation on the economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and Wellness education programs focused on chronic disease - -H.R 1427, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -H.R, 1548, Pathway for Biosimiloars Act: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics -S.726, Promoting Innovation and Access to Life-Saving Medicine: regulatory approval for follow-on biologics,including provisions on data exclusivity and patient procedures for biologics
Client expense: — · Firm income: $110,000
Matched citations: S.726
Source: Senate LDA